REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
13

MOTS-c Journey — Month 3 Check-In

Raven Ingram·about 2 months ago
Month 3 check-in for my MOTS-c journey. Quick recap: 35-year-old, recreational athlete, running this primarily for recovery and longevity goals. Month 1 was the adjustment period. Getting used to the routine, dialing in timing and injection technique. Minimal noticeable effects beyond placebo territory. Month 2 is when things got interesting. Sleep metrics improved across the board. HRV started trending upward. Recovery between training sessions shortened. I was hitting PR territory in the gym which I attribute partly to being able to train harder and more frequently. Month 3 has been about maintaining the gains. The dramatic improvement phase seems to be over, replaced by a steady state of enhanced baseline function. I feel notably better than pre-protocol but the week-to-week improvements have leveled off. Interesting observation: I took a long weekend trip in month 2 and missed 3 consecutive doses. Did not notice any immediate decline, which suggests the effects are more cumulative than acute. Resumed dosing when I returned and everything stayed on track. Planning to continue for one more month and then take a 6-week break to see how much of the benefit persists.

Comments (5)

Merit EmersonDEMO·about 2 months ago

Real talk: MOTS-c worked well for me but the cost is significant. For anyone considering it, I would suggest doing a proper cost-benefit analysis first. Calculate the total cost for a full protocol and honestly assess whether the expected benefits justify that investment.

5
Beau GuthrieDEMO·about 2 months ago

Interesting data. My MOTS-c experience was somewhat different — I noticed effects earlier than you did, probably because I started at a higher initial dose. Trade-off was more pronounced side effects in week 1 that resolved by week 2. Neither approach is wrong, just different risk-reward profiles.

2
North AustinDEMO·about 2 months ago

This thread has been incredibly helpful for understanding MOTS-c. I have been on the fence about starting for months and reading detailed real-world experiences like these has been more useful than any blog post or article I have found. The fact that most reports here are moderate rather than extreme actually increases my confidence.

3
Drew HendersonDEMO·about 2 months ago

One thing I wish more MOTS-c discussions covered is the discontinuation experience. What happens when you stop? In my case, the benefits gradually faded over about 3-4 weeks after stopping. Sleep was the first thing to return to baseline. Recovery improvements lasted a bit longer. Worth knowing for planning protocol duration.

4
Dana GrahamDEMO·about 2 months ago

Great point about bloodwork. I ran comprehensive panels at baseline, 6 weeks, and 12 weeks during my MOTS-c protocol. The most informative markers for me were inflammatory markers and IGF-1 levels. Would strongly recommend anyone running MOTS-c to invest in proper monitoring.

5

Sign in to comment.